Early research which points us to new cancer therapeutic opportunities

Have you ever wondered why some anti-cancer agents do well and others poorly – even with similar…

May 11, 2023

The road less travelled

Off the beaten track can bring danger and delight in the unknown in equal measure

May 2, 2023

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

This time of year always brings a flurry of data across different conferences as we start winding up our…

April 27, 2023

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

The ever evolving selective KRAS inhibitor & degrader space

March 29, 2023

AACR23 Preview 5 – an emerging landscape

A look at an emerging early stage oncology landscape

March 23, 2023

AACR23 Preview 4 – Stepping It Up

Continuing our evaluation and exploration of another batch of early stage anti-cancer compounds either…

March 20, 2023

Cracking the code to the MYC oncogene

A novel approach to targeting an intractable oncogene

January 23, 2023

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023

On the prickly issues facing the Menin inhibitors

Some key subtleties and nuances to watch out for in the Menin niche

December 13, 2022

Tilting at windmills

The importance of T cell exhaustion and exploring ways to avoid it

December 5, 2022

Dancing with Cancer Cells

The beat goes on for synthetic lethal approaches

November 17, 2022

On overcoming resistance to protein degraders

Are there opportunities for combining small molecule inhibitors with protein degraders?

October 19, 2022

SITC22 Preview 1 – Looking under the hood

6 abstracts to watch out for on how to overcome immune escape

October 12, 2022

New directions and opportunities with intractable oncology targets

Just because a pathway has been called undruggable doesn't always mean it will be so!

March 15, 2022

A fine line between failure and success

9 hidden Gems from the ASH21 poster hall and why you should pay attention to them

December 17, 2021

Targeting Menin and the evolving landscape for NPM1-MLLr acute leukemias

A look at new data in the Menin/MLLr inhibitor landscape in acute leukemias

April 20, 2021

5 early developments to watch out for at AACR21

What's hot in early preclinical development to watch out for?

April 5, 2021

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021

ASH Day 1 highlights and lowlights Part 2

Highlights on translational research and clinical trials in AML and BCLA CAR T cell therapy

December 6, 2020

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

Standing out from the crowd

One particular presentation stood out from the others at AACR20 this year

April 29, 2020

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020

Novel Targets and Agents – Part 2

In the first part of the review on novel targets in hematologic malignancies, we covered five key areas…

March 20, 2020

Will 2020 be an inflection year for Kura Oncology?

Update on Kura Oncology's progress with tipifarnib and their emerging pipeline

January 16, 2020

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019

On the interaction between transcription factors and the immune system

A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...

August 26, 2019

ASH Preview 2 – Developmental Therapeutics

A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?

November 29, 2017

Can we target p53 therapeutically?

What's new about p53 mutants and MDM2 inhibitors?

February 7, 2019

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017

AACR 2017 Preview 3

After exploring a mechanistic approach and a tumour type as part of our AACR annual meeting coverage, in…

March 8, 2017

Novel Targets in Multiple Myeloma

Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?

February 8, 2017

Novel targets and approaches in triple negative breast cancer

What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.

April 1, 2014